NCT05041062 2024-01-03A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal MesotheliomaUniversity of ChicagoPhase 2 Completed2 enrolled 8 charts